Biotech is always an interesting opportunity.

New innovation, retiring baby boomers, and the need for better care will always ensure that biotech will remain strong. Often, it's the most innovative biotech stocks with upcoming trial news we want to pay the most attention to.

Here are three of those very opportunities.

Geron Corporation (NASDAQ:GERN)

The company is developing a first-in-class inhibitor, imetelstat, for patients afflicted with a blood-based malignancy, known as lower risk myelodysplastic syndromes (MDS). The company believes this treatment could generate sales of more than $500 million. That’s quite a potential payday for a company with a market cap of $354.17 million.Geron expects to initiate a Phase III study in low-risk MDS this year. The treatment has already demonstrated efficacy in myelofibrosis, or MF patients that have not done as well with other drugs.

TG Therapeutics (NASDAQ:TGTX)

The company is developing two therapies targeting hematological malignancies and autoimmune diseases.Biotech is always an exciting trade. And from what we can see from TGTX study data, this stock could be just as exciting. In a mid-stage trial for refractory marginal zone lymphoma (MZL), the drug easily met its primary endpoint of overall response rate. The FDA also just granted umbralisib a Breakthrough Therapy Designation for the treatment.Even better, the drug is currently showing a favorable efficacy when compared to other drugs, including an AbbVie drug treatment. Should all go according to plan, the company could be on track to see a few hundred million dollars in annual sales.

Moleculin Biotech (NASDAQ:MBRX)

Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma.

It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous Tcell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers.The company announced that its ongoing research at The University of Texas Anderson Cancer Center has shown that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animals.